Loading clinical trials...
Loading clinical trials...
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial
Conditions
Interventions
Cyclosporine
Fludarabine Phosphate
+5 more
Locations
3
United States
LDS Hospital
Salt Lake City, Utah, United States
Veterans Administration Center-Seattle
Seattle, Washington, United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
January 1, 2006
Primary Completion Date
September 1, 2017
Completion Date
March 1, 2018
Last Updated
January 31, 2020
NCT06439199
NCT04239157
NCT05636514
NCT06859424
NCT06994676
NCT06523556
Lead Sponsor
Fred Hutchinson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions